Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments

mAbs

Volumn 9, Issue 1, 2017, Pages 68-84

  Egan, Timothy J ^a,b   Diem, Dania ^a   Weldon, Richard ^a   Neumann, Tessa ^a   Meyer, Sebastian ^a   Urech, David M ^a  

^a Numab AG   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

Antibody; antibody fragment; framework; heterodimer; humanization; multispecific; tetraspecific

Indexed keywords

INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 5 RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRASTUZUMAB; TUMOR NECROSIS FACTOR; ANTIBODY; RECOMBINANT PROTEIN;

ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIBODY STRUCTURE; BINDING ASSAY; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIMERIZATION; HETERODIMERIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; THERMOSTABILITY; ANTIBODY SPECIFICITY; BIOSYNTHESIS; CHEMISTRY; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; PROTEIN CONFORMATION; PROTEIN STABILITY;

ANTIBODIES; ANTIBODY SPECIFICITY; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; PROTEIN CONFORMATION; PROTEIN STABILITY; RECOMBINANT PROTEINS;

EID: 85002322910     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1248012     Document Type: Article

References (64)

1. Doppalapudi VR, Huang J, Liu D, Jin P, Liu B, Li L, Desharnais J, Hagen C, Levin NJ, Shields MJ, et al. Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A 2010; 107:22611-6; PMID:21149738; http://dx.doi.org/10.1073/pnas.1016478108
2. Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol [Internet] 2014; 32:191-8. Available from:http://www.ncbi.nlm.nih.gov/pubmed/24463572; PMID:24463572; http://dx.doi.org/10.1038/nbt.2797
3. Liu Z, Leng EC, Gunasekaran K, Pentony M, Shen M, Howard M, Stoops J, Manchulenko K, Razinkov V, Liu H, et al. A Novel Antibody Engineering Strategy for Making Monovalent Bispecific Heterodimeric IgG Antibodies by Electrostatic Steering Mechanism. J Biol Chem [Internet] 2015; 290:7535-62. Available from:http://www.jbc.org/content/290/12/7535.abstract; PMID:25583986; http://dx.doi.org/10.1074/jbc.M114.620260
4. Weidle UH, Tiefenthaler G, Weiss EH, Georges G, Brinkmann U. The intriguing options of multispecific antibody formats for treatment of cancer. Cancer Genomics and Proteomics 2013; 10:1-18; PMID:23382582
5. Smith AJ. New Horizons in Therapeutic Antibody Discovery:Opportunities and Challenges versus Small-Molecule Therapeutics. J Biomol Screen [Internet] 2014; 20:437-53. Available from:http://jbx.sagepub.com/cgi/doi/10.1177/1087057114562544; PMID:25512329; http://dx.doi.org/10.1177/1087057114562544
6. Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol [Internet] 2015; 67:95-106. Available from:http://dx.doi.org/10.1016/j.molimm.2015.01.003; PMID:25637431; http://dx.doi.org/10.1016/j.molimm.2015.01.003
7. Brack S, Attinger-Toller I, Schade B, Mourlane F, Klupsch K, Woods R, Hachemi H, von der Bey U, Koenig-Friedrich S, Bertschinger J, et al. A Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action. Mol Cancer Ther [Internet] 2014; 13:2030-9. Available from:http://www.ncbi.nlm.nih.gov/pubmed/24994770; PMID:24994770; http://dx.doi.org/10.1158/1535-7163.MCT-14-0046-T
8. Dong J, Sereno A, Snyder WB, Miller BR, Tamraz S, Doern A, Favis M, Wu X, Tran H, Langley E, et al. Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem [Internet] 2011; 286:4703-17. Available from:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3039382&tool=pmcentrez&rendertype=abstract; PMID:21123183; http://dx.doi.org/10.1074/jbc.M110.184317
9. Jost C, Schilling J, Tamaskovic R, Schwill M, Honegger A, Pückthun A. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. Structure 2013; 21:1979-91; PMID:24095059; http://dx.doi.org/10.1016/j.str.2013.08.020
10. Dennis MS, Zhang M, Gloria Meng Y, Kadkhodayan M, Kirchhofer D, Combs D, Damico LA. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 2002; 277:35035-43; PMID:12119302; http://dx.doi.org/10.1074/jbc.M205854200
11. Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, Atwal J, Elliott JM, Prabhu S, Watts RJ, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 2011; 3:84ra44; PMID:21613623; http://dx.doi.org/10.1126/scitranslmed.3002230
12. Dennis MS, Watts RJ. Transferrin antibodies into the brain. Neuropsychopharmacology [Internet] 2012; 37:302-3. Available from:http://dx.doi.org/10.1038/npp.2011.196; PMID:22157868; http://dx.doi.org/10.1038/npp.2011.196
13. Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, Bien-Ly N, Hersom M, Maloney J a, Meilandt WJ, et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci Transl Med [Internet] 2014; 6:261ra154. Available from:http://www.ncbi.nlm.nih.gov/pubmed/25378646\nhttp://stm.sciencemag.org/content/6/261/261ra154.full.pdf; PMID:25378646; http://dx.doi.org/10.1126/scitranslmed.3009835
14. Wunder A, Muller-Ladner U, Stelzer EH, Funk J, Neumann E, Stehle G, Pap T, Sinn H, Gay S, Fiehn C. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol [Internet] 2003; 170:4793-801. Available from:http://www.ncbi.nlm.nih.gov/pubmed/12707361; PMID:12707361; http://dx.doi.org/10.4049/jimmunol.170.9.4793
15. Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, et al. Targeted therapy with the T-cell - Engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29:2493-8; PMID:21576633; http://dx.doi.org/10.1200/JCO.2010.32.7270
16. Linke R, Klein A, Seimetz D. Catumaxomab:Clinical development and future directions. MAbs 2010; 2:129-36; PMID:20190561; http://dx.doi.org/10.4161/mabs.2.2.11221
17. Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 2015; 67:95-106; PMID:25637431; http://dx.doi.org/10.1016/j.molimm.2015.01.003
18. Castoldi R, Jucknischke U, Pradel LP, Arnold E, Klein C, Scheiblich S, Niederfellner G, Sustmann C. Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties. Protein Eng Des Sel 2012; 25:551-9; PMID:22936109; http://dx.doi.org/10.1093/protein/gzs048
19. Schubert I, Kellner C, Stein C, Kügler M, Schwenkert M, Saul D, Mentz K, Singer H, Stockmeyer B, Hillen W, et al. A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting. MAbs 2011; 3:21-30; PMID:21081841; http://dx.doi.org/10.4161/mabs.3.1.14057
20. Kügler M, Stein C, Kellner C, Mentz K, Saul D, Schwenkert M, Schubert I, Singer H, Oduncu F, Stockmeyer B, et al. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol 2010; 150:574-86; PMID:20636437; http://dx.doi.org/10.1111/j.1365-2141.2010.08300.x
21. Schoonjans R, Willems A, Schoonooghe S, Fiers W, Grooten J, Mertens N. Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives. J Immunol 2000; 165:7050-7; PMID:11120833; http://dx.doi.org/10.4049/jimmunol.165.12.7050
22. Li Z, Krippendorff B-F, Sharma S, Walz AC, Lavé T, Shah DK. Influence of molecular size on tissue distribution of antibody fragments. MAbs [Internet] 2016; 8:113-9. Available from:http://www.ncbi.nlm.nih.gov/pubmed/26496429; PMID:26496429; http://dx.doi.org/10.1080/19420862.2015.1111497
23. Vossen ACTM, Tibbe GJM, Kroos MJ, van de Winkel JGJ. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects. Eur J Immunol 1995; 25:1492-6; PMID:7614975; http://dx.doi.org/10.1002/eji.1830250603
24. Röthlisberger D, Honegger A, Plückthun A. Domain interactions in the Fab fragment:A comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J Mol Biol 2005; 347:773-89; PMID:15769469; http://dx.doi.org/10.1016/j.jmb.2005.01.053
25. Wu H, Kroe-Barrett R, Singh S, Robinson AS, Roberts CJ. Competing aggregation pathways for monoclonal antibodies. FEBS Lett [Internet] 2014; 588:936-41. Available from:http://dx.doi.org/10.1016/j.febslet.2014.01.051; PMID:24530501; http://dx.doi.org/10.1016/j.febslet.2014.01.051
26. Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD. Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies. Mol Cancer Ther 2012; 11:1467-76; PMID:22564724; http://dx.doi.org/10.1158/1535-7163.MCT-11-1038
27. Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm 2009; 24:155-61; PMID:19409036; http://dx.doi.org/10.1089/cbr.2009.0627
28. Holliger P, Prospero T. “Diabodies”:Small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A 1993; 90:6444-8; PMID:8341653; http://dx.doi.org/10.1073/pnas.90.14.6444
29. Zhu Z, Presta LG, Zapata G, Carter P. Remodeling domain interfaces to enhance heterodimer formation. Protein Sci 1997; 6:781-8; PMID:9098887; http://dx.doi.org/10.1002/pro.5560060404
30. Ewert S, Honegger A, Plückthun A. Stability improvement of antibodies for extracellular and intracellular applications:CDR grafting to stable frameworks and structure-based framework engineering. Methods 2004; 34:184-99; PMID:15312672; http://dx.doi.org/10.1016/j.ymeth.2004.04.007
31. Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, Hoess A, Wölle J, Plückthun A, Virnekäs B. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol 2000; 296:57-86; PMID:10656818; http://dx.doi.org/10.1006/jmbi.1999.3444
32. Eigenbrot C, Randal M, Presta L, Carter P, Kossiakoff AA. X-ray Structures of the Antigen-binding Domains from Three Variants of Humanized anti-p185HER2 Antibody 4D5 and Comparison with Molecular Modeling. J. Mol. Biol.1993; 229:969-95; PMID:8095303; http://dx.doi.org/10.1006/jmbi.1993.1099
33. Honegger A, Plückthun A. Yet another numbering scheme for immunoglobulin variable domains:an automatic modeling and analysis tool. J Mol Biol [Internet] 2001; 309:657-70. Available from:http://www.sciencedirect.com/science/article/pii/S0022283601946625; PMID:11397087; http://dx.doi.org/10.1006/jmbi.2001.4662
34. Rader C, Ritter G, Nathan S, Elia M, Gout I, Jungbluth AA, Cohen LS, Welt S, Old LJ, Barbas CF. The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies. J Biol Chem 2000; 275:13668-76; PMID:10788485; http://dx.doi.org/10.1074/jbc.275.18.13668
35. Lavinder JJ, Hoi KH, Reddy ST, Wine Y, Georgiou G. Systematic characterization and comparative analysis of the rabbit immunoglobulin repertoire. PLoS One 2014; 9:1-11; PMID:24978027; http://dx.doi.org/10.1371/journal.pone.0101322
36. Borras LJ, Urech D. Humanization of rabbit antibodies using a universal antibody framework. U.S. Patent Number 8,293,235. Filed on June 25, 2009.
37. Borras L, Gunde T, Tietz J, Bauer U, Hulmann-Cottier V, Grimshaw JPA, Urech DM. Generic approach for the generation of stable humanized single-chain Fv fragments from rabbit monoclonal antibodies. J Biol Chem 2010; 285:9054-66; PMID:20056614; http://dx.doi.org/10.1074/jbc.M109.072876
38. Willuda J, Honegger A, Waibel R, Schubiger PA, Stahel R, Zangemeister-Wittke U, Plückthun A. High Thermal Stability Is Essential for Tumor Targeting of Antibody Fragments. Cancer Res 1999; 59:5758-67; PMID:10582696
39. Rosenberg AS. Effects of protein aggregates:an immunologic perspective. AAPS J 2006; 8:E501-7; PMID:17025268; http://dx.doi.org/10.1208/aapsj080359
40. Joubert MK, Hokom M, Eakin C, Zhou L, Deshpande M, Baker MP, Goletz TJ, Kerwin BA, Chirmule N, Narhi LO, et al. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem 2012; 287:25266-79; PMID:22584577; http://dx.doi.org/10.1074/jbc.M111.330902
41. Lalor P, Nossal G, Sanderson R, McHeyzer-Williams M. Functional and molecular characterization of single, (4-hydroxy-3-nitrophenyl)acetyl (NP)-specific, IgG1+ B cells from antibody-secreting and memory B cell pathways in the C57BL/6 immune response to NP. Eur J Immunol 1992; 22:3001-11; PMID:1425924; http://dx.doi.org/10.1002/eji.1830221136
42. Lightwood DJ, Carrington B, Henry AJ, McKnight AJ, Crook K, Cromie K, Lawson ADG. Antibody generation through B cell panning on antigen followed by in situ culture and direct RT-PCR on cells harvested en masse from antigen-positive wells. J Immunol Methods 2006; 316:133-43; PMID:17027850; http://dx.doi.org/10.1016/j.jim.2006.08.010
43. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotný J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R. Protein engineering of antibody binding sites:recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A [Internet] 1988; 85:5879-83. Available from:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=281868&tool=pmcentrez&rendertype=abstract; PMID:3045807; http://dx.doi.org/10.1073/pnas.85.16.5879
44. Brüsselbach S, Korn T, Völkel T, Müller R, Kontermann R. Enyzme recruitment and tumor cell killing in vitro by a secreted bispecific single-chain diabody. Tumor Target 1999; 4:115-23
45. Schaefer J V, Plückthun A. Transfer of engineered biophysical properties between different antibody formats and expression systems. Protein Eng Des Sel 2012; 25:485-505; PMID:22763265; http://dx.doi.org/10.1093/protein/gzs039
46. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu R-R, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25:1290-7; PMID:17934452; http://dx.doi.org/10.1038/nbt1345
47. Steinmetz A, Vallée F, Beil C, Lange C, Baurin N, Beninga J, Capdevila C, Corvey C, Dupuy A, Ferrari P, et al. CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications. MAbs [Internet] 2016; 8:867-78. Available from:http://dx.doi.org/10.1080/19420862.2016.1162932; PMID:26984268; http://dx.doi.org/10.1080/19420862.2016.1162932
48. Honegger A, Malebranche AD, Röthlisberger D, Plückthun A. The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains. Protein Eng Des Sel 2009; 22:121-34; PMID:19136675; http://dx.doi.org/10.1093/protein/gzn077
49. Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today [Internet] 2015; 20:838-47. Available from:http://dx.doi.org/10.1016/j.drudis.2015.02.008; PMID:25728220; http://dx.doi.org/10.1016/j.drudis.2015.02.008
50. Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011; 108:11187-92; PMID:21690412; http://dx.doi.org/10.1073/pnas.1019002108
51. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009; 69:4941-4; PMID:19509221; http://dx.doi.org/10.1158/0008-5472.CAN-09-0547
52. Moore PA, Zhang W, Rainey GJ, Burke S, Li H, Huang L, Gorlatov S, Veri MC, Aggarwal S, Yang Y, et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 2011; 117:4542-51; PMID:21300981; http://dx.doi.org/10.1182/blood-2010-09-306449
53. Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth CW, Matys ER, Little M. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol [Internet] 1999; 293:41-56. Available from:http://www.sciencedirect.com/science/article/pii/S002228369993156X; PMID:10512714; http://dx.doi.org/10.1006/jmbi.1999.3156
54. Hu S, Fu W, Xu W, Yang Y, Cruz M, Berezov SD, Jorissen D, Takeda H, Zhu W. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer Res 2015; 75:159-70; PMID:25371409; http://dx.doi.org/10.1158/0008-5472.CAN-14-1670
55. Li Z, Krippendorff B-F, Sharma S, Walz AC, Lavé T, Shah DK. Influence of molecular size on tissue distribution of antibody fragments. MAbs 2016; 8:113-9; PMID:26496429; http://dx.doi.org/10.1080/19420862.2015.1111497
56. Wu H, Kroe-Barrett R, Singh S, Robinson AS, Roberts CJ. Competing aggregation pathways for monoclonal antibodies. FEBS Lett 2014; 588:936-41; PMID:24530501; http://dx.doi.org/10.1016/j.febslet.2014.01.051
57. LaFleur DW, Abramyan D, Kanakaraj P, Smith RG, Shah RR, Wang G, Yao X-T, Kankanala S, Boyd E, Zaritskaya L, et al. Monoclonal antibody therapeutics with up to five secificities:functional enhancement through fusion of target-specific peptides. MAbs 2013; 5:1-11; PMID:23254906; http://dx.doi.org/10.4161/mabs.23043
58. Ewert S, Huber T, Honegger A, Plückthun A. Biophysical properties of human antibody variable domains. J Mol Biol [Internet] 2003; 325:531-53. Available from:http://www.ncbi.nlm.nih.gov/pubmed/12498801\nhttp://linkinghub.elsevier.com/retrieve/pii/S0022283602012378; PMID:12498801; http://dx.doi.org/10.1016/S0022-2836(02)01237-8
59. Zhu Z, Zapata G, Shalaby R, Snedecor B, Chen H, Carter P. High level secretion of a humanized bispecific diabody from Escherichia coli. Nat Biotechnol 1996; 14:303-8; PMID:9630890; http://dx.doi.org/10.1038/nbt0296-192
60. Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, Friedrich M, Thomas O, Lorenczewski G, Rau D, et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci U S A 2010; 107:12605-10; PMID:20616015; http://dx.doi.org/10.1073/pnas.1000976107
61. Vigneri PG, Tirr∫ E, Pennisi MS, Massimino M, Stella S, Romano C, Manzella L. The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy. Front Oncol [Internet] 2015; 5:230. Available from:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4606066&tool=pmcentrez&rendertype=abstract; PMID:26528439; http://dx.doi.org/10.3389/fonc.2015.00230
62. Coloma MJ, Morrison SL. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 1997; 15:159-63; PMID:9035142; http://dx.doi.org/10.1038/nbt0297-159
63. Niesen FH, Berglund H, Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc [Internet] 2007; 2:2212-21. Available from:http://www.nature.com/doifinder/10.1038/nprot.2007.321; PMID:17853878; http://dx.doi.org/10.1038/nprot.2007.321
64. Honegger A, Plückthun A. Yet another numbering scheme for immunoglobulin variable domains:an automatic modeling and analysis tool. J Mol Biol 2001; 309:657-70; PMID:11397087; http://dx.doi.org/10.1006/jmbi.2001.4662